QIAGEN NV (QGEN) said Thursday that the US Food and Drug Administration has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, marking the company's second FDA clearance of a QIAstat-Dx panel in 2025.
The company said it has now received regulatory clearances for three mini panels for the detection of respiratory and gastrointestinal conditions, which are designed for outpatient use to aid fast treatment decisions.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.